Summary
EudraCT Number: 2008-006905-18
Sponsor's Protocol Code Number: MP-TOCTAP-2008
National Competent Authority: Germany - BfArM 
Clinical Trial Type: EEA CTA
Trial Status: Prematurely Ended
Date on which this record was first entered in the EudraCT database: 2010-07-27
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006905-18/DE/

A. Protocol Information
A.1 Member State Concerned: Germany - BfArM
A.2 EudraCT number: 2008-006905-18
A.3 Full title of the trial: Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus Tolcapon

TOCTAP (Treatment of Cognitive Deficits in Schizophrenia with Tolcapone and Pergolide)

A.3.2 Name or abbreviated title of the trial where available: TOCTAP
A.4.1 Sponsor's protocol code number: MP-TOCTAP-2008
A.5.1 ISRCTN (International Standard Randomised Controlled Trial) number: 42412532
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: RWTH Aachen University
B.1.3.4	Country: Germany
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Tasmar
D.2.1.1.2 Name of the Marketing Authorisation holder: Valeant Pharmaceuticals Ltd.
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Tolcapon
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: TOLCAPONE
D.3.9.1 CAS number: 134308-13-7
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 100 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Parkotil
D.2.1.1.2 Name of the Marketing Authorisation holder: Lilly Deutschland GmbH
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Pergolid
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: PERGOLIDE MESILATE
D.3.9.1 CAS number: 66104232
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 0,05 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Parkotil
D.2.1.1.2 Name of the Marketing Authorisation holder: Lilly Deutschland GmbH
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Pergolid
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: PERGOLIDE MESILATE
D.3.9.1 CAS number: 66104232
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 0,25 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Tablet
D.8.4 Route of administration of the placebo: Oral use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Das vorliegende Projektvorhaben dient der Untersuchung, inwieweit bei Patienten mit schizophrenen Störungen neben einer bestehenden Monotherapie mit Paliperidon (Invega), dem zuletzt zugelassenen neuartigen Antipsychotikum der sog. zweiten Generation, eine additive prodopaminerge Psychopharmakotherapie mit Tolcapon (Tasmar) oder Pergolid (Parkotil) die präfrontalen kognitiven Funktionen beeinflusst. 
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Verbesserung präfrontaler kognitiver Funktionen bei Patienten mit schizophrenen Störungen. Hauptzielparameter ist die Veränderung des MCCB nach 6 Wochen gegenüber dem Vor-wert. 
E.2.2 Secondary objectives of the trial: Kenntnisse über die Modulierbarkeit beeinträchtigter kognitiver Funktionen bei Patienten mit schizophrenen Störungen gewonnen werden. Dies bietet die Basis für neue therapeutische Optionen zur Verbesserung des sozialen Funktionsniveaus bei Erkrankten. 
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: -	unterschirebene Einverständniserklärung
-               Alter 18 - 50 Jahre
-	Diagnose Schizophrenie nach DSM-IV.
-	Bei Frauen: negativer Schwangerschaftstest
-	Keine Substanzabhängigkeit
-	Zweifelsfreies Verständnis der Studienaufklärung
-	Fähigkeit, die deutsche Sprache zu lesen, zu verstehen und zu schreiben,
-	Keine schwerwiegenden sonstigen medizinischen Erkrankungen, kein Anfallsleiden
-	Keine Suizidalität

E.4 Principal exclusion criteria: -	Abhängigkeit von illegalen Drogen
-	Nachweis von illegalen Drogen in der Urinprobe
-	Schwerwiegende körperliche Erkrankungen die nach Art und Schwere mit der geplanten Untersuchung interferieren oder den Probanden akut gefährden
-	Long-QT-Syndrom, Bekannte Herzrhythmusstörungen, sowie Einnahme von Medikamenten, die eine QT- Verlängerung verursachen
-	Anatomisch nachgewiesenen Veränderungen jeglicher Herzklappen (z.B. echokardiographisch sichtbare Klappensegelverdickung, Einschränkung der Klappenbeweglichkeit, kombinierte Klappenbeweglichkeitseinschränkung-Stenosierung).
-	Peptischer Ulcus, Colitis Ulcerosa, paralytischer Ileus in der Vorgeschichte
-	Seltene hereditäre Erkrankungen wie Galactose-Intoleranz, Lactase-Mangel oder Glucose-Galactose-Malabsorption
-	Epilepsie
-	Eingeschränkte Nieren- oder Leberfunktion
-	Klinisch bedeutsame Abweichungen in der klinischen Chemie oder Hämatologie oder klinisch bedeutsame Auffälligkeiten im EEG oder EKG
-	Schwangerschaft oder Stillzeit
-	Fehlende sichere Verhütungsmaßnahmen (genaue Definition der sicheren und unsicheren Verhütungsmethoden wird mündlich und schriftlich erfolgen). 
-	Personen, die in einem Abhängigkeits- / Arbeitsverhältnis zum Sponsor oder Prüfer stehen 
-	Unfähigkeit, das Studienprotokoll einzuhalten, beschränkte oder vollständig aufgehobene Geschäftsfähigkeit
-	Es werden keine aufgrund gerichtlicher oder behördlicher Anordnung in einer Anstalt untergebrachten Personen in die Prüfung einbezogen.
-	Bekannte Unverträglichkeit der Studienmedikation.

E.5 End points
E.5.1 Primary end point(s): Ergebnisse der neuropsychologischen Testung (t-Werte)
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: No
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: Yes
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): Yes
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: No
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: Yes
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 2
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Ein persönlicher Follow-up-Kontakt (Visite 8) erfolgt am 49. Studientag, nach 8 Wochen sowie nach insgesamt zwölf Wochen (Visite 9 + 10) eine letzte telefonische Kontaktaufnahme
Die Teilnehmer der Studie haben die Möglichkeit, jederzeit ihre Teilnahmeeinwilligung zurückzunehmen und die Teilnahme an der Studie zu beenden. 


E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 2
E.8.9.2 In all countries concerned by the trial months: 0
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): No
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2010-07-27) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: Yes
F.3.3.7.1 Details of other specific vulnerable populations: none
F.4 Planned number of subjects to be included
F.4.1 In the member state: 60
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 60
F.4.2.2 In the whole clinical trial: 60

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2010-07-22
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2010-01-11

P. End of Trial
P. End of Trial Status: Prematurely Ended
P. Date of the global end of the trial: 2019-09-30

